ALK: We examined the ALK gene as it is a common biomarker in patients with non-small-cell lung cancer (NSCLC) and is the primary target of many chemotherapeutic treatments used to treat NSCLC and anaplastic large cell lymphomas (ALCL). This evidence concerns the gene ALK and non-small cell lung carcinoma.